Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H14N3O3.Br.BrH |
Molecular Weight | 397.063 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.[Br-].N[C@]2(C[N+]1=CC=CC=C1)C[C@@H](NC2=O)C(O)=O
InChI
InChIKey=GIZKBHWITTWBAP-IEQXMABBSA-N
InChI=1S/C11H13N3O3.2BrH/c12-11(7-14-4-2-1-3-5-14)6-8(9(15)16)13-10(11)17;;/h1-5,8H,6-7,12H2,(H-,13,15,16,17);2*1H/t8-,11+;;/m1../s1
Molecular Formula | BrH |
Molecular Weight | 80.912 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C11H13N3O3 |
Molecular Weight | 235.2392 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:37:10 GMT 2023
by
admin
on
Sat Dec 16 11:37:10 GMT 2023
|
Record UNII |
869R8A3UZS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
953074-84-5
Created by
admin on Sat Dec 16 11:37:10 GMT 2023 , Edited by admin on Sat Dec 16 11:37:10 GMT 2023
|
PRIMARY | |||
|
300000010720
Created by
admin on Sat Dec 16 11:37:10 GMT 2023 , Edited by admin on Sat Dec 16 11:37:10 GMT 2023
|
PRIMARY | |||
|
24826985
Created by
admin on Sat Dec 16 11:37:10 GMT 2023 , Edited by admin on Sat Dec 16 11:37:10 GMT 2023
|
PRIMARY | |||
|
869R8A3UZS
Created by
admin on Sat Dec 16 11:37:10 GMT 2023 , Edited by admin on Sat Dec 16 11:37:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Laboratoires Prodimed; Class: Amino acid, Antineoplastic, Pyridinium compound; Mechanism of Action: Immunomodulator; Orphan Drug Status: Yes for Renal cancer; Highest Development Phase: Phase I for Solid tumours; Most Recent Event: 11 Jul 2011 Phase-I clinical trials in Solid tumours in Spain (unspecified route)
|